Last reviewed · How we verify

NCT06588244: INOCA-NA

INOCA-NA a Local Prospective Registry

Recruiting now Last updated 17 March 2025
What this trial tests

trial in Ischemia, Myocardial in 250 participants. Currently enrolling.

Timeline
19 September 2024
Primary endpoint
1 September 2026
1 September 2027

Quick facts

Lead sponsorFederico II University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment250
Start date19 September 2024
Primary completion1 September 2026
Estimated completion1 September 2027
Sites1 location across Italy

Conditions studied

Sponsor

Federico II University

Who can join

Eligibility, any sex, with Ischemia, Myocardial or Non-Obstructive Coronary Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study has the following objectives: 1. To investigate the prevalence of INOCA in patients referring for a clinically indicated coronary angiography (CA) c/o Division of Cardiology - Federico II University Hospital; 2. To stratify in INOCA endotypes patients according to the presence or absence of alternative (i.e. non obstructive CAD) causes of myocardial ischemia detected during CA clinically indicated through physiology tests; 3. to implement a stratified therapy in these patients considering the different INOCA endotypes and evaluate the impact on angina class and quality of life as well as cardiac hospitalization and coronary revascularization during 5 year follow up

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ischemia, Myocardial

Currently open trials in the same condition.

Other Federico II University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06588244.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing